Phenothiazinyl-2-essigsaeure | 20965-69-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: Phenothiazinyl-2-essigsaeure
• 英文别名: (10H-phenothiazin-2-yl)-acetic acid；phenothiazin-2-yl-acetic acid；Phenothiazin-2-yl-essigsaeure；phenothiazine-2-acetic acid；2-(10H-phenothiazin-2-yl)acetic acid
• CAS: 20965-69-9
• 化学式: C₁₄H₁₁NO₂S
• 分子量: 257.313
• InChiKey: IFKVERMEMGDLLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Phenothiazinyl-2-essigsaeure 生成 (10H-phenothiazin-2-yl)-acetic acid methyl ester
  参考文献：
  名称：

  Messer; Farge; Guyonnet, Arzneimittel-Forschung/Drug Research, 1969, vol. 19, # 8, p. 1193 - 1198

  摘要：

  DOI：
• 作为产物：
  描述：

  ss-(2-Phenothiazinyl)-thioacetomorpholid 在 potassium carbonate 、 硫酸 作用下， 以 乙醇 、 水 为溶剂， 反应 17.0h， 以67%的产率得到Phenothiazinyl-2-essigsaeure
  参考文献：
  名称：

  Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments

  摘要：

  该发明涉及与通式（I）相对应的2-羟基四氢呋喃衍生物，其中A代表基团，其中R1、R2、R4、R5和R6代表（特别是），独立地为H、卤素原子、OH、烷基或烷氧基，R3代表H、烷基或—COR10，R10代表H、烷基或烷氧基，W代表键，—CH2—CH2—、—CH═CH—、—O—、—S—或—NR11—，其中R11代表H或烷基；X代表—CO—、—Y—CO—、—O—Y—CO—或—NR12—Y—CO—，Y代表烷基或卤代烷基，R12代表H、烷基或—COR13，R13代表H、烷基、卤代烷基或烷氧基，AA代表，每次出现时，一个天然或非天然氨基酸；n代表2或3；最后R代表H、烷基或—CO—R19，R19代表烷基。这些化合物具有抑制钙蛋白酶活性和/或捕获活性氧物质的活性，可用于制备用于治疗炎症和免疫性疾病、心血管和脑血管疾病、中枢或外周神经系统疾病、虚弱、骨质疏松症、肌肉萎缩症、增殖性疾病、白内障、器官移植后的排斥反应以及自身免疫和病毒性疾病的药物。

  公开号：

  US20050222045A1

文献信息

• PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS
  申请人：KEIL Stefanie

  公开号：US20090325942A1

  公开（公告）日：2009-12-31

  The invention relates to compounds of the formula 1, wherein R1, R2, R3, R4, R5, R6, R7, A and B are as defined herein, the pharmaceutical compositions and the uses as pharmaceuticals.

  这项发明涉及公式1的化合物，其中R1、R2、R3、R4、R5、R6、R7、A和B如本文所定义，以及作为药物的药物组合物和用途。
• Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments
  申请人：Auvin Serge

  公开号：US20050222045A1

  公开（公告）日：2005-10-06

  The invention relates to derivatives of 2-hydroxytetrahydrofuran corresponding to general formula (I) in which A represents the radical, in which R 1 , R 2 , R 4 , R 5 and R 6 represent (in particular), independently, H, a halogen atom, OH, alkyl or alkoxy, R 3 represents H, alkyl or —COR 10 , R 10 representing H, alkyl or alkoxy, and W represents a bond, —CH 2 —CH 2 —, —CH═CH—, —O—, —S— or —NR 11 — in which R 11 represents H or alkyl; X represents —CO—, —Y—CO—, —O—Y—CO— or —NR 12 —Y—CO—, Y represents an alkylene or haloalkylene alkyl, R 12 represents H, alkyl or —COR 13 , R 13 represents H, alkyl, haloalkyl or alkoxy, AA represents, each time that it occurs, a natural or non-natural amino acid; n represents 2 or 3; and finally R represents H, alkyl or —CO—R 19 , R 19 representing alkyl. These compounds have a calpain inhibiting activity and/or an activity which traps the reactive oxygen species and can be used for preparing a medicament intended to treat the inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or peripheral nervous system, cachexia, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following organ transplants and autoimmune and viral diseases.

  该发明涉及与通式（I）相对应的2-羟基四氢呋喃衍生物，其中A代表基团，其中R1、R2、R4、R5和R6代表（特别是），独立地为H、卤素原子、OH、烷基或烷氧基，R3代表H、烷基或—COR10，R10代表H、烷基或烷氧基，W代表键，—CH2—CH2—、—CH═CH—、—O—、—S—或—NR11—，其中R11代表H或烷基；X代表—CO—、—Y—CO—、—O—Y—CO—或—NR12—Y—CO—，Y代表烷基或卤代烷基，R12代表H、烷基或—COR13，R13代表H、烷基、卤代烷基或烷氧基，AA代表，每次出现时，一个天然或非天然氨基酸；n代表2或3；最后R代表H、烷基或—CO—R19，R19代表烷基。这些化合物具有抑制钙蛋白酶活性和/或捕获活性氧物质的活性，可用于制备用于治疗炎症和免疫性疾病、心血管和脑血管疾病、中枢或外周神经系统疾病、虚弱、骨质疏松症、肌肉萎缩症、增殖性疾病、白内障、器官移植后的排斥反应以及自身免疫和病毒性疾病的药物。
• Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments
  申请人：Auvin Serge

  公开号：US20060166893A1

  公开（公告）日：2006-07-27

  A hydroxytetrahydrofuran of formula wherein A is with the substituents as defined in the specification, having a calpain inhibiting activity and/or an activity which traps the reactive oxygen species useful for treating inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or peripheral nervous system, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following organ transplants and autoimmune and viral diseases.

  一种羟基四氢呋喃，其化学式为其中A为，在规范中定义的取代基，具有钙蛋白酶抑制活性和/或捕获反应性氧化物种的活性，可用于治疗炎症和免疫性疾病、心血管和脑血管疾病、中枢或外周神经系统疾病、骨质疏松症、肌肉萎缩症、增生性疾病、白内障、器官移植后的排斥反应以及自身免疫和病毒性疾病。
• Novel dual inhibitors of calpain and lipid peroxidation with enhanced cellular activity
  作者：Serge Auvin、Bernadette Pignol、Edith Navet、Morgane Troadec、Denis Carré、José Camara、Dennis Bigg、Pierre-E. Chabrier

  DOI：10.1016/j.bmcl.2005.12.036

  日期：2006.3

  A series of dipeptides with dual inhibitory activities on calpain and lipid peroxidation were prepared to target the intracellular calpain. This optimization program focused on the variations of the linker and the N-terminal amino acid of the peptidic core. Two compounds 6d-05 and 6d-08 exhibited potent intracellular calpain inhibition. The polar surface area and the number of rotors appeared to be critical descriptors to account for the behavior of these hybrid molecules in the cellular calpain assay. (C) 2005 Elsevier Ltd. All rights reserved.
• Mediators suitable for the electrochemical regeneration of NADH, NADPH or analogs thereof
  申请人：Bayer Corporation

  公开号：EP0704535B1

  公开（公告）日：2001-11-28